PTC/SB/26 (09-04)
Approved for use through 07/31/2006 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are regulated to respond to a collection of information unities it displays a valid OMB control number

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) 04-1011-C
In re Application of: Pascal Družgala	
Application No.: 10/763,904	
Filed: January 23, 2004	
For Utrashort Acting Hypnotic Barbiturates	
The owner", ARY's Therapeurica Inc. of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No 6,387,914 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns	
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent. 'as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent (ater. expires for failure to pay a maintenance fee; is held unenforceable;	
is found invalid by a court of competent jurisdiction. Is statutorly disclaimed in whote or terminally disclaimed under 37 CFR 1.321; That all claims canceled by a reexamination certificate; Is reissued; or	
is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate	
For submissions on behalf of a pusiness/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2 The undersigned is an attorney or agent of record. Reg. No. 37,142	
Wille Dy W	July 12, 2005
Signature	Date
Michael S. Greenfield	
Typed or printed name	
	312-913-0001
<u></u>	Telephone Number
Terminal disclaimer fee under 37 CFR 1 20(d) included. Please charge the fee under 37 CFR 1 20(d) to deposit account 13-2480	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038	
"Statement under 37 CFR 3 73(b) is required if terminal disclaimer is signed by the assignee (owner) Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 97 CFR 1 921. The information is required to obtain or retain a penefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete including stitlering, preparing, and submitting the completed application form to the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burtien, should be sent to the Chief information Officer, U.S. Patient and Tiedemark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need dissistance in completing the form, call 1-500-PTO-9199 and adject oponn 2